Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 20/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16098047 | 0.95 | WNT3A (0.80) | WNT3A | |
| SCHEMBL18007189 | 0.91 | WNT3A (0.75) | WNT3A | |
| SCHEMBL18029813 | 0.90 | WNT3A (0.71) | WNT3A | |
| SCHEMBL16097797 | 0.90 | WNT3A (0.70) | WNT3A | |
| SCHEMBL16098122 | 0.89 | WNT3A (1.00) | WNT3A | |
| SCHEMBL18029730 | 0.89 | WNT3A (0.70) | WNT3A | |
| SCHEMBL16098671 | 0.89 | WNT3A (1.00) | WNT3A | |
| SCHEMBL18007196 | 0.88 | WNT3A (0.73) | WNT3A | |
| SCHEMBL18007194 | 0.88 | WNT3A (0.72) | WNT3A | |
| SCHEMBL18007176 | 0.88 | WNT3A (0.76) | WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160052898-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-25 | — | — | US | claimed |
| EP-2976343-A2 | SUBSTITUTED N-BIPHENYL-3-ACETYLAMINO-BENZAMIDES AND N-[3-(ACETYLAMINO)PHENYL]-BIPHENYL-CARBOXAMIDES AND THEIR USE AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | Bayer Pharma Aktiengesellschaft (DE) | 2016-01-27 | — | — | EP | claimed |
| WO-2014147182-A2 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-25 | — | — | WO | claimed |
| US-20180244783-A1 | COMBINATION THERAPY FOR TREATMENT OF DISEASE | ONCOMED PHARMACEUTICALS, INC. | 2018-08-30 | — | — | US | disclosed |
| WO-2017040666-A2 | COMBINATION THERAPY FOR TREATMENT OF DISEASE | ONCOMED PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| US-20160052898-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-25 | — | — | US | disclosed |
| US-20160052898-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-25 | — | — | US | disclosed |
| EP-2976343-A2 | SUBSTITUTED N-BIPHENYL-3-ACETYLAMINO-BENZAMIDES AND N-[3-(ACETYLAMINO)PHENYL]-BIPHENYL-CARBOXAMIDES AND THEIR USE AS INHIBITORS OF THE WNT SIGNALLING PATHWAY | Bayer Pharma Aktiengesellschaft (DE) | 2016-01-27 | — | — | EP | disclosed |
| WO-2014147182-A2 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014147182-A2 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052898-A1 | NOVEL COMPOUNDS | AADAC, NAT1, CCNA1 | WNT3A 4230/4885 |
| US-20180244783-A1 | COMBINATION THERAPY FOR TREATMENT OF DISEASE | WNT1, WNT3, WNT3A | WNT3A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.